Cardiology

Top Story

PATHWAY-2: Spironolactone benefits patients with resistant hypertension

August 31, 2015

Read the Perspective from José Ramón González-Juanatey, MD, PhD, FESC, FACC

LONDON — In patients with resistant hypertension despite guideline-directed medical therapy, the addition of spironolactone produced a greater reduction in BP than the addition of an alpha-blocker or beta-blocker, and enabled a majority of patients to bring their hypertension under control, according to the results of the PATHWAY-2 study.

“The result in favor of spironolactone is unequivocal,” Bryan Williams, MD, FRCP, FESC, FAHA, chair of medicine at University College London, said during a European Society of Cardiology Congress press conference. “Spironolactone is the most effective treatment for resistant hypertension. These results should directly influence guideline treatment of 100 million people globally.”

In the Journals

Diabetes, depression predict poor survival, rehospitalization in patients with heart failure

August 31, 2015
Poorer survival and rehospitalization in patients with heart failure are associated with comorbid diabetes and depressive symptoms, according to recent study findings…
In the Journals

Readmission rates may skew hospital quality measurements

August 31, 2015
Readmission rates were an ineffective measure of a hospital’s quality because they did not take into account readmissions from different hospitals, resulting in a…
Meeting News Coverage

ARTS-HF: Finerenone effective, safe in patients hospitalized for worsening HF

August 31, 2015
LONDON — In patients hospitalized for worsening HF, finerenone and eplerenone yielded similar decreases in the cardiac biomarker NT-proBNP at 90 days, but…
Luigi Di Biase, MD Meeting News CoveragePerspective

BELIEF: LAA isolation during catheter ablation benefited patients with persistent AF

August 31, 2015
LONDON — Isolating the left atrial appendage during catheter ablation was associated with a greater rate of freedom from recurrence of atrial fibrillation in…
More News Headlines »
CME
Managing Today's EP Challenges with NOAC Use

Managing Today's EP Challenges with NOAC Use

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.

This engaging activity featuring a superb faculty provides electrophysiologists and others with the best information…
More »
Meeting News Coverage Video
VIDEO: ED protocol with high-sensitivity troponin assays helps rule out MI quickly

VIDEO: ED protocol with high-sensitivity troponin assays helps rule out MI quickly

August 30, 2015
LONDON — Joseph S. Alpert, MD, professor of medicine at the University of Arizona College of Medicine…
More »
CME
Highlights from Lipid Forum 2015™: Focus on Hypertriglyceridemia

Highlights from Lipid Forum 2015®: Focus on Hypertriglyceridemia

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent yet modifiable risk factor for atherosclerotic disease, pancreatitis, and…
More »
morganatic-roan